Dactinomycin-induced veno-occlusive disease in rats. The hepatoprotective action of amifostine. Evaluation in a light and electron microscope.
The purpose of the study was to draw upan experimental model of hepatic veno-occlusive disease (VOD) induced by dactinomycin (ACT) and to investigate the possible hepatoprotective effects of Ethyol (amifostine). Pathological changes corresponding to a VOD picture of varying intensification were found in the liver samples obtained from all the rats receiving ACT. Amifostine appears to act protectively to liver changes caused by dactinomycin.
Borowska
Halina
H
Department of Histology and Embryology, Medical University, Białystok, Poland. histolog@amb.edu.pl
Arciszewska
Ewa
E
Czauderna
Piotr
P
Sawicki
Bogusław
B
D004999:Amifostine / Q000494:pharmacology; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000633:toxicity*; D003609:Dactinomycin / Q000008:administration & dosage / Q000633:toxicity*; D004336:Drug Antagonism; D006003:Glycogen / Q000378:metabolism; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D022781:Hepatocytes / Q000187:drug effects / Q000648:ultrastructure; D007274:Injections, Intraperitoneal; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D010503:Periodic Acid-Schiff Reaction; D011837:Radiation-Protective Agents / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D000903:Antibiotics, Antineoplastic; D011837:Radiation-Protective Agents; D003609:Dactinomycin; D006003:Glycogen; D004999:Amifostine